Abstract
Objectives: We evaluated the significance of urinary retinoic acid receptor-beta 2 (RAR-beta 2) gene promoter methylation and hyaluronidase activity in comparison with voided urine cytology (VUC) in diagnosis of bladder cancer.
Design and Methods: This study included 100 patients diagnosed with bladder cancer, 65 patients with benign urological disorders and 51 healthy volunteers. Urine supernatant was used for determining hyaluronidase activity by zymography while urine sediment was used for cytology and detection of methylated RAR-beta 2 gene promoter by methylation specific nested PCR.
Results: The sensitivity and specificity were 53% and 90.5% for VUC, 65% and 89.7% for percent methylation fraction of RAR-beta 2 gene promoter, and 89% and 90.5% for hyaluronidase activity; combination of the three parameters increased sensitivity to 95%. A significant association was observed between investigated markers and advanced grade tumor.
Conclusions: Combined use of RAR-beta 2 gene promoter methylation, hyaluronidase activity and VUC is promising non-invasive tool for bladder cancer detection. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.